{
  "documentMetadata": {
    "title": "Bacteremia, Salmonella sp.",
    "lastUpdated": "2021-11-15",
    "sourceFile": "Bacteremia, Salmonella sp..pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 2,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Bacteremia is an extra-intestinal manifestation of Salmonella-related diarrheal disease. Referred to as \"enteric fever\" when diarrhea is absent.",
        "Generally acquired by ingestion of contaminated water or food.",
        "Classically enteric fever is caused by Salmonella Serotype Typhi or Salmonella Serotype Paratyphi (often abbreviated as Salmonella Typhi or Salmonella Paratyphi).",
        "Bacteremia risk groups include:",
        "  Very young children and very old adults",
        "  Immunosuppressed patients",
        "  HIV/AIDS",
        "  Liver disease",
        "  Sickle cell disease",
        "  Gastric acid suppression",
        "  Recent use of antibiotics (within 30 days)",
        "  In the developing world, children with malaria, anemia or malnutrition",
        "Manifestations in Children ([Adv Pediatr 62:29, 2015](https://www.advances.theclinics.com/article/S0065-3101(15)00029-7/fulltext)).",
        "Non typhoidal Salmonella non-diarrheal illness, including sepsis and other invasive disease, seen in patients with malignancies ([BMJ Inf Dis 21:1021 2021](https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06720-5)).",
        "See also: Typhoid Fever"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Salmonella enterica a variety of serotypes including Typhi, Paratyphi, Enteriditis, Typhimurium and Choleraesuis"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Ciprofloxacin 400 mg IV q12h or 750 mg po q12h",
        "Levofloxacin 750 mg po/IV q24h",
        "Duration of therapy depends on the presence or absence of extra-intestinal infection:",
        "  If no extra-intestinal infection, treat for 14 days",
        "  If extra-intestinal infection (e.g., mycotic aneursym, osteomyelitis) or if immunosuppressed, may need up to 4-6 weeks of therapy"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Ceftriaxone 2 gm IV q24h for 14 days if no extra-intestinal infection; up to 6 weeks if mycotic aneurysm",
        "Other less commonly used drugs: TMP-SMX 8-10 mg/kg/day of TMP component divided q8h; duration as above",
        "If highly resistant organism or empiric therapy of severe infection in a patient from Pakistan, Southeast Asia, Africa: Meropenem 1-2 gm IV q8h x 14 days, longer for mycotic aneurysm."
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Patient can be transitioned to an oral regimen once afebrile and clinically stable.",
        "Emerging resistance in the developing world (particularly Pakistan and Southeast Asia), so treatment should be based upon the likely geographic origin of isolate.",
        "In vitro resistance to nalidixic acid is a surrogate marker for relative resistance to fluoroquinolones and an alternative regimen should be used.",
        "Treatment should be guided by direct antimicrobial testing.",
        "If Salmonella Serotype Typhi in a non traveller, assume XDR https://emergency.cdc.gov/han/2021/han00439.asp and treat with a carbapenem."
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Increasing resistance to first-line agents among US non-typhoidal isolates from blood for 2003-13: approximately 6% for Ceftriaxone, 6% for Ciprofloxacin, 22% for TMP/SMX, 3% resistant to all three ([J Infect Dis 214:1565, 2016](https://academic.oup.com/jid/article/214/10/1565/2529310)).",
        "Parallel increases in resistance in food (esp poultry) and environmental isolates for NTS [Transbound Emerg Dis 2021 doi: 10.1111/tbed.14362](https://onlinelibrary.wiley.com/doi/10.1111/tbed.14362)",
        "CDC advisory for outbreak of extensively drug-resistant typhoid fever in Pakistan: https://wwwnc.cdc.gov/travel/notices/alert/xdr-typhoid-fever-pakistan and a second XDR outbreak in Iraq [MMWR Morb Mortal Wkly Rep.69: 618 2020](https://www.cdc.gov/mmwr/volumes/69/wr/mm6921a4.htm)",
        "Fluoroquinolone resistance",
        "  CLSI has established new interpretive breakpoints for susceptibility to Ciprofloxacin ([Clin Infect Dis 55:1107, 2012](https://academic.oup.com/cid/article/55/8/1107/289539))",
        "  Susceptible strains: MIC < 0.06 Âµg/mL",
        "  Higher MICs (0.12-1.0, intermediate and > 2.0, resistant) correlate with presence of mutations in gyrA, gyrB, or plasmid-mediated fluoroquinolone resistance",
        "  For commercial antimicrobial susceptibility test systems that have not incorporated lower dilutions into test panels either Ciprofloxacin Etest or disk diffusion testing with both ciprofloxacin (zone diameter > 31 mm indicates susceptible) and nalidixic acid are recommended to detect decreased Ciprofloxacin susceptibility and high level resistance",
        "Bacteremia can result in infection of lungs, urinary tract, joints, CNS, cardiac valves, and elsewhere.",
        "Increased risk of seeding atherosclerotic plaques in the aorta or older patients.",
        "Increased risk of osteomyelitis in sickle cell patients.",
        "Reference of clinical presentation: [Am J Emerg Med 32:1241, 2014](https://www.ajemjournal.com/article/S0735-6757(14)00493-X/fulltext)."
      ]
    }
  ]
}